News Releases
ReBio Technologies Completes Pre-IND Meeting: Clearing Path direct to Phase II for RBLP sustained release treatment for glaucoma
ReBio today announced that is has completed a Type B pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding ReBio’s proposed development program for RBLP in the treatment of mild to moderate primary open-angle glaucoma.
ReBio Technologies Announces the formation of a Scientific Advisory Board
ReBio today announced today the formation and members of its Scientific Advisory Board (SAB), comprised of leaders in ophthalmology and ophthalmic drug delivery
ReBio Technologies Receives 410K Euros Funding from Business Finland to advance its SiSu® platform for ophthalmic therapeutics.
ReBio today announced that it has received a 410K Euros funding from Business Finland to support the development of SiSu®, ReBio’s proprietary phase-inverting anhydrous liquid polymer formulation platform, for the treatment of chronic eye diseases.
ReBio Technologies Announces the Successful Completion of Seed Financing.
ReBio Technologies Ltd. announced today that it closed a $2 million seed round, and welcomed WI Harper (WIH) as new investors.